Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer
NCODA Oncology and Hematology Meeting Abstracts · 15.06.2026
DOI: 10.67209/ywzs9808 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 15.06.2026. Verfasst von Donald Richards und 5 weiteren Autor:innen. Die Arbeit nennt 2 Literaturangaben.
Abstract (Originalsprache)
Trifluridine/tipiracil (FTD-TPI; LONSURF) is an oral antineoplastic agent approved for 3rd-line use in combination with or without bevacizumab (BEV) in metastatic colorectal cancer (mCRC). In the Phase III SUNLIGHT trial, the addition of BEV to FTD-TPI was associated with a significant improvement in overall survival (OS) and progression-free survival (PFS) compared to FTD-TPI monotherapy. However, data on the use of FTD-TPI in combination with BEV in the real-world community setting are currently limited.
Zitieren
APA
Richards, D., Zhao, R., Khan, N., Chang, B., Mahmud, S., & Salimi, T. (2026). Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/ywzs9808
Vancouver
Richards D, Zhao R, Khan N, Chang B, Mahmud S, Salimi T. Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/ywzs9808
BibTeX
@article{Richards2026,
author = {Richards, Donald and Zhao, Ruizhi and Khan, Nadeem and Chang, Brenda and Mahmud, Siraje and Salimi, Tehseen},
title = {Real-world treatment patterns and outcomes with trifluridine/tipiracil monotherapy or in combination with bevacizumab in metastatic colorectal cancer},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/ywzs9808}
}
EUVIMED